Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.

@article{Shorr2004LinezolidFT,
  title={Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.},
  author={Andrew F. Shorr and Gregory M. Susla and Marin H Kollef},
  journal={Critical care medicine},
  year={2004},
  volume={32 1},
  pages={
          137-43
        }
}
OBJECTIVES To determine the incremental cost-effectiveness of linezolid compared with vancomycin for treatment of ventilator-associated pneumonia due to Staphylococcus aureus. DESIGN Decision model analysis of the cost and efficacy of linezolid vs. vancomycin for treatment of ventilator-associated pneumonia. The primary outcome was the incremental cost-effectiveness of linezolid in terms of cost per added quality-adjusted life-year gained. Other outcomes were the marginal costs per hospital… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

Pharmacoeconomics of linezolid.

  • Expert opinion on pharmacotherapy
  • 2008
VIEW 16 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus

  • PharmacoEconomics
  • 2007
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.

  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States.

  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2017

Cost-effectiveness and Pricing of Antibacterial Drugs

  • Chemical biology & drug design
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND